2025. Formulation and Development of HA BSA Coated NLC Containing Fisetin and Flavokawain A for the Treatment of Lung Carcinoma. Journal of Carcinogenesis. 24, 8s (Oct. 2025), 553–562. DOI:https://doi.org/10.64149/J.Carcinog.24.8s.553-562.